Streetbeat News

Products Services

JNJ

Global health aid agency Unitaid is urging Johnson & Johnson (JNJ) to expand access to its tuberculosis (TB) drug, bedaquiline, particularly in countries with high TB cases. Unitaid has called on JNJ's CEO to remove all secondary patents, allowing for the production of generic versions of the drug. JNJ has confirmed its commitment not to enforce patents for bedaquiline in 134 designated low- and middle-income countries.

Portfolio Pulse from Vandana Singh

October 02, 2023 | 4:28 pm

AAPL

GOOGL

MSFT

Microsoft's CEO, Satya Nadella, testified in the Google antitrust trial, highlighting the potential of AI in enhancing search capabilities. He expressed concerns that Google could leverage its substantial search-related earnings to secure exclusive content rights, enhancing its AI and further extending its market lead. Nadella also mentioned Microsoft's failed attempts to position Bing as the default search app on Apple's products.

Portfolio Pulse from Anusuya Lahiri

October 02, 2023 | 4:11 pm

SPHR

Sphere Entertainment Co. (NASDAQ:SPHR) shares are trading higher after its debut concert in Las Vegas, NV. The event created a buzz in the media, attracting attention from retail investors and short-sellers. More than 1.4 million shares have been traded on Monday, compared to the stock's 100-day average of just over 529 thousand shares. Sphere shares are up 14.5% at $42.55.

Portfolio Pulse from Erica Kollmann

October 02, 2023 | 4:01 pm

AMZN

BROG

DHR

MSFT

TSLA

Bitcoin has hit a 6-week high of over $28,000. Analysts predict a bullish trend for Bitcoin, Ethereum, and Dogecoin. Amazon.com is predicted to have over 35% upside according to an analyst with an 83% accuracy rate. Stocks of Danaher and Brooge Energy are moving lower in pre-market trading. Tesla's Elon Musk denies making $8.6M every hour and disputes reports of Tesla's stock drops. Microsoft's Satya Nadella is set to testify in Google's antitrust trial.

Portfolio Pulse from Akanksha Bakshi

October 02, 2023 | 3:53 pm

SNDX

Syndax Pharmaceuticals Inc announced topline data from the AUGMENT-101 trial of revumenib in patients with acute myeloid leukemia and acute lymphoid leukemia. The trial met its primary endpoint with a complete remission rate of 23% among the 57 efficacy evaluable patients. However, the company is stopping the trial to further accrual in the KMT2Ar cohorts based on the Independent Data Monitoring Committee recommendation. SNDX shares are down 9.09% at $13.20.

Portfolio Pulse from Vandana Singh

October 02, 2023 | 3:51 pm

ICCM

IceCure Medical Ltd (NASDAQ:ICCM) announced new data validating its ProSense Cryoablation as a safe and effective outpatient procedure for breast cancer with a 96.8% success rate. The study used ProSense for cryoablation treatment of 31 patients with early-stage breast cancer who declined surgery. The company's shares are up 46.40% at $0.79 on the last check Monday.

Portfolio Pulse from Vandana Singh

October 02, 2023 | 3:44 pm

NVTA

The FDA has granted de novo approval for Invitae Corporation's Common Hereditary Cancers Panel, a diagnostic test that can detect genetic variants associated with an elevated risk of developing certain cancers. The test, which is the first to be granted FDA marketing authorization, evaluates DNA from a blood sample to identify variants in 47 genes. Invitae tested over 9,000 clinical samples to validate the test's performance, achieving over 99.0% accuracy. The approval also creates a new regulatory classification, allowing future tests of the same type to use the FDA's 510(k) premarket process. Invitae's shares are up 13.70%.

Portfolio Pulse from Vandana Singh

October 02, 2023 | 3:37 pm

NVO

Novo Nordisk has received FDA approval for Rivfloza, a treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disease. The approval is based on the results of the phase 2 PHYOXTM2 clinical trial and interim data from the ongoing phase 3 PHYOXTM3 extension study. Rivfloza was developed by Dicerna Pharmaceuticals, which was acquired by Novo Nordisk in 2021. The company plans to make the treatment available for eligible patients in early 2024.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 3:16 pm

UBS

UBS Asset Management is launching its first live pilot program of a tokenized money market fund on Ethereum. The pilot is part of a broader industry initiative led by the Monetary Authority of Singapore, Project Guardian, which aims to bring different real-world assets on-chain and utilize blockchain technology to enhance market liquidity. The pilot will be used by UBS Asset Management for activities like fund subscriptions and redemptions. The project is part of UBS Asset Management’s global distributed ledger technology strategy.

Portfolio Pulse from Khyathi Dalal

October 02, 2023 | 2:36 pm

HMC

TSLA

WKSP

Tesla continues to dominate the US EV market, but the landscape is evolving. Honda is reentering the EV market with the 2024 Honda Prologue, developed with General Motors' Ultium battery platform. However, legacy automakers like GM, Ford, and Stellantis face challenges due to an ongoing UAW strike. Meanwhile, Worksport Ltd is developing a solar-powered tonneau cover and remote battery system that could disrupt the EV market.

Portfolio Pulse from Upwallstreet

October 02, 2023 | 2:32 pm